Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTI-203 in Moderate-to-Severe ARDS
NCT05947955Phase 2Recruiting
- Sponsor
- BioAegis Therapeutics
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Rhu-pGSN Treatment with Normal Saline Placebo (2 arms). Primary endpoint: All-cause mortality at day 28. Started Oct 2024; status: recruiting.
02
Drugs
Recombinant human plasma gelsolin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05947955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947955.